ZeroStack Corp. (ZSTK) Options Positioning, Max Pain & Unusual Sweeps

$2.93 -0.34% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $2.92

ZeroStack Corp. (ZSTK) carries a Roarable Rating of E (Strong Sell) with 31/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

ROARABLE E β€’ RED ALERT Cap $63.9M
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on ZSTK Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-01, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.93 (-0.34% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #931 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does ZSTK compare to ESYN and COSM in the Health Care sector?
β–Ό

Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for ZSTK?
β–Ό

Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $2.92 (-0.25%)🧬 Dilution Drag (+2.48% YoY Shares)βš™οΈ Cash Engine: 4/20 (E) β€’ 0% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record Warning: Scores below 50 (31/100 Β· E) historically underperformed SPY in 71% of rolling 90-day windows (-9.4% avg 90D alpha vs SPY β€’ 29.0% hit rate).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERRED ALERT β€’ E
025507510031
3-of-3 JEV AI Jury Bearish Warning
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw E Β· Rk D-
Cash (4)Whales (7)SEC (10)Macro (7)CEO (3)
Each axis scored 0–20
12M PRICE TARGET CONE-12.3% Base Target
$16 Bull$3 Base$2 Bear
πŸ“¬ FREE ZSTK RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for ZSTK)Realized 20D OHLCV Swing Band: Β±12.5%
Deterministic 5-Pillar Attribution (31/100 Composite)
πŸ” WHY ZSTK SCORES 31/100 (E) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+10/20 pts (32% of score)

Altman Z-Score 3.80 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 2/9

β–² #2 Bullish Driver: Whale & Options Positioning+7/20 pts (23% of score)

20D Institutional Volume Accumulation (Β±12.5% realized swing band)

β–Ό #1 Drag / Risk Factor: Insider Conviction & Share Dilution4/20 pts (-16 pt drag)

Dilution Drag (+2.48% YoY Shares) & executive Form 4 sales trim 16 pts from alignment

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
39
Grade E$4.62-13.4% Next Q
Q2 (-2Q)
36
Grade E$4.00-18% Next Q
Q3 (-1Q)
34
Grade E$3.28-10.7% Next Q
Current
31
Grade E$2.93-9.4% Hist 90D Ξ±
Trajectory: E (39) β†’ E (31)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a ZSTK Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While ZSTK currently carries a cautious 31/100 (E) rating due to Insider Conviction & Share Dilution (4/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Established market leader in Health Care with deep daily trading liquidity.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($4.40) and Max Pain ($3.08) forces dealer call-delta covering toward $15.79.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Dilution Drag (+2.48% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $ZSTKβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œZSTK Beats Next Quarter EPS Consensus (Dec 30, 2026) & Holds Above 200D SMA”
CALL VS. PUT WHALE SHARE
β€” (No Active Options Snapshot)
Put/Call Ratio: β€” (No Active Options Snapshot)
MAX-PAIN EXPIRATION MAGNET
β€” (No Active Options Snapshot)
No active options chain max-pain snapshot on file
HISTORICAL 20D VOLATILITY SWING
Β±12.5%
Derived from 20D OHLCV bars (No Active Options Snapshot)

Active Strike Call vs. Put Concentration Ladder (ZSTK)

β€” (No Active Options Snapshot) β€” No unusual CBOE strike concentration anomalies recorded in the current database snapshot for ZSTK.

Sponsored / Partner SpotlightACTIVE TRADER & PROP EVALUATION DESK

Practice in Our Weekly $100,000 Paper Arena Before Risking Personal Capital

Keep your personal nest egg in cash while trading NQ, ES, Crude, and Gold momentum using institutional prop-desk buying power.

FTC Disclosure: Roarable may receive partner referral compensation at no cost to you. Partner relationships never influence RQD scores.

πŸ† Enter Free $100K Paper Arena β†’
ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring ZSTK)

  • βœ“Walkthrough of ZSTK's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
ZSTK // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -50.84%πŸ“ HORIZONTAL RANGE
2026-10-30O $3.18H $3.18L $2.78C $2.93VOL 3.9K
SUP: $-1.90SMA50: $4.40SMA200: $5.16
$13.57$10.25$6.93$3.61$0.29SUP $-1.90$2.932026-04-302026-06-152026-07-312026-09-162026-10-30
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

ZSTK Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
8.0%/yr Implied 5Y Growth

vs. -0.5% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on ZSTK today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for ZSTK. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for ZSTK today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (ZSTK)

1. Head-to-Head Health Care Peer Comparison (ZSTK vs. ESYN, COSM, NUS, MEDS)

Industry: Other Pharmaceuticals (10 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, ZeroStack Corp. (ZSTK) ranks #931 by composite RQD confidence (31/100, grade E) and #720 by equity capitalization ($63.9M). Within this direct 5-issuer industry benchmark cohort, ZSTK leads on earnings valuation at N/A trailing P/E, while NUS leads on capital efficiency and profitability with 6.7% ROIC and 69.4% gross margin. NUS currently holds the highest overall quantitative score in the immediate peer group at 62/100 (C) compared with ZSTK at 31/100 (E).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
ZSTK ACTIVE
ZeroStack Corp.
E 31/100 β€” 4.6% -35.0% -0.34% $63.9M Benchmark Subject
ESYN
EnerSyn Global Inc.
D- 41/100 β€” 53.0% -35.0% +3.10% $54.4M /esyn-vs-zstk β†’
COSM
Cosmos Health Inc.
E 31/100 β€” 12.1% -35.0% +11.45% $27.9M /cosm-vs-zstk β†’
NUS
Nu Skin Enterprises Inc.
C 62/100 β€” 69.4% 6.7% -1.47% $228.3M /nus-vs-zstk β†’
MEDS
DataMeds AI Inc.
E 30/100 β€” -27.5% -35.0% -7.73% $9.8M /meds-vs-zstk β†’

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K β€’ FILED 2025-12-31 β€’ CIK 0001790169

In its most recent audited fiscal period (FY2025, filed 2025-12-31), ZeroStack Corp. (ZSTK) reported GAAP revenue of $35.7M (-0.5% vs. FY2024 revenue of $35.9M , and -53.1% cumulative change since FY2023) , GAAP net income of $0, operating cash flow of -$8.7M, and free cash flow of -$8.8M (-70.4% YoY). On the balance sheet, ZSTK closed FY2025 with $130.2M in total assets against $50.8M in total debt (Altman Z-Score: N/A, Piotroski F-Score: 2/9).

Fiscal Period Filing Date Revenue Net Income Operating Cash Flow Free Cash Flow Total Assets Total Debt
FY2025 (FY) 2025-12-31 $35.7M $0 -$8.7M -$8.8M $130.2M $50.8M
FY2024 (FY) 2024-12-31 $35.9M -$15.9M -$5.0M -$5.2M $26.2M $0
FY2023 (FY) 2023-12-31 $76.1M -$57.0M -$8.4M -$8.4M β€” β€”

3. ZSTK Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is ZSTK stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, ZeroStack Corp. (NASDAQ: ZSTK) is rated E (Strong Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 31/100 at a spot price of $2.93 (-0.34% 1D, market cap $63.9M). Pillar breakdown: Fundamental Cash Engine 4/20, Institutional 13F & Options Flow 7/20, Executive Insider Alignment 10/20, FRED Macro Regime Fit 7/20, and SEC Balance-Sheet Forensics 3/20. Across 1016 tracked Health Care issuers, ZSTK ranks #931 in composite RQD confidence.

How does ZSTK compare to ESYN and COSM in the Health Care sector?

Within the Health Care sector (Other Pharmaceuticals), ZSTK carries a Roarable E (31/100 RQD), trailing P/E of N/A, gross margin of 4.6%, and ROIC of -35.0%. By comparison, ESYN (EnerSyn Global Inc.) holds a D- grade (41/100 RQD, P/E N/A, ROIC -35.0%, cap $54.4M) and COSM (Cosmos Health Inc.) posts a E grade (31/100 RQD, P/E N/A, ROIC -35.0%, cap $27.9M). Among the 5-stock peer group, ZSTK leads on earnings multiple (N/A) while NUS leads on capital efficiency (6.7% ROIC).

What are the biggest fundamental strengths and SEC risk factors for ZSTK?

Per ZSTK's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001790169), ZeroStack Corp. generated $35.7M in revenue (-0.5% YoY), $0 in net income, and -$8.8M in free cash flow against $130.2M in total assets and $50.8M in total debt. Key quantitative strengths: Established market leader in Health Care with deep daily trading liquidity.. Primary risk factors monitored: Company executives have done more routine share selling than personal cash buying lately.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is ZSTK trading relative to its 50-day, 200-day, and 52-week technical levels?

ZSTK last traded at $2.93 (-0.34% on volume of 79,396 shares), positioning the stock -33.41% below its 50-day simple moving average ($4.40) and -43.22% below its 200-day simple moving average ($5.16). Across its 52-week range of $1.32 to $15.04, ZSTK sits at the 11.7% percentile with a 14-day RSI of 25.0 (OVERSOLD (<32)) and an implied next-earnings move of Β±12.5% ($2.56 to $3.30).

ZSTK Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

What is ZSTK's options positioning and volatility profile?

Roarable tracks verified CBOE unusual options sweeps, put/call ratios, and OHLCV realized volatility bands for ZSTK.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $213.66 -0.80% AAPL $348.91 +1.48% MSFT $530.14 -0.16% TSLA $403.30 -0.23% PLTR $196.42 -0.20% SOFI $17.61 +2.74% IBIT $43.36 -0.94% GLD $355.78 -1.34%